DBV Technologies (NASDAQ:DBVT) Shares Cross Below 50-Day Moving Average - Should You Sell?

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report)'s share price crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $9.18 and traded as low as $8.51. DBV Technologies shares last traded at $8.52, with a volume of 55,727 shares traded.

Analyst Ratings Changes

Several brokerages have recently commented on DBVT. Wall Street Zen raised shares of DBV Technologies from a "sell" rating to a "hold" rating in a research note on Friday, May 9th. The Goldman Sachs Group raised shares of DBV Technologies to a "sell" rating and set a $7.25 price objective for the company in a research note on Thursday, May 29th. JMP Securities reaffirmed a "market outperform" rating and set a $21.00 price objective on shares of DBV Technologies in a research note on Thursday. Lifesci Capital raised shares of DBV Technologies to a "strong-buy" rating in a research note on Thursday. Finally, Citigroup reaffirmed an "outperform" rating on shares of DBV Technologies in a research note on Tuesday, May 27th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, DBV Technologies presently has a consensus rating of "Moderate Buy" and an average price target of $14.75.

DBV Technologies Price Performance

The company has a market capitalization of $251.58 million, a P/E ratio of -1.87 and a beta of -0.63. The stock's 50 day moving average is $9.24 and its 200-day moving average is $6.30.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its quarterly earnings results on Friday, April 11th. The company reported ($1.10) earnings per share (EPS) for the quarter. DBV Technologies had a negative return on equity of 278.24% and a negative net margin of 3,249.99%. The company had revenue of $0.51 million during the quarter. On average, equities research analysts anticipate that DBV Technologies S.A. will post -7.05 EPS for the current year.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC purchased a new position in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies at the end of the most recent reporting period. 71.74% of the stock is owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.